Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

664.52 -3.43 (-0.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
News headline image
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
Analysts have given Alnylam Pharmaceuticals an average price target of $436. 
Via The Motley Fool
News headline image
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% ↗
It might pull it off, provided several things fall right in place. 
Via The Motley Fool
Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗
Via Chartmill
REGN (NASDAQ:REGN) Presents a Classic Value Opportunity with Strong Fundamentals ↗
Via Chartmill
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
These stocks are better bets to skyrocket than the much-hyped rocket stock. 
Via The Motley Fool
News headline image
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested ↗
Parabilis Medicines is ambitious, but it has Regeneron on its side already. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Underrated Weight Loss Stocks to Buy and Hold ↗
They look well-positioned to grab a slice of the fast-growing anti-obesity market. 
Via The Motley Fool
News headline image
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This Stock Is Up 58% This Year. Is It too Late to Buy? ↗
There could be additional catalysts for this drugmaker over the next year. 
Via The Motley Fool
News headline image
3 Profitable Stocks We Think Twice About
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
From Pomerantz LLP
Via GlobeNewswire
Top S&P500 movers in Monday's session ↗
Via Chartmill
News headline image
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Regeneron (REGN) Stock Is Trading Up Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 2.9% in the afternoon session after the company announced an expanded cancer therapy ... 
Via StockStory
News headline image
2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
3 Nasdaq 100 Stocks We Find Risky
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win... 
Via StockStory
News headline image
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN): Grabar Law Office is Investigating Claims on Your
From Grabar Law Office
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Important Notice to Long-Term Shareholders of Molina Healthcare, Inc. (NYSE: MOH); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Grabar Law Office is Investigating Claims on
From Grabar Law Office
Via GlobeNewswire
News headline image
Amylyx Stock: Why the Full Pipeline Story Matters ↗
Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares 
Via MarketBeat
News headline image
Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron
Check out the companies making headlines this week: Toll Brothers (NYSE:TOL): Homebuilding company Toll Brothers (NYSE:TOL) rose by 8.3% on Wednesday after t... 
Via StockStory
Topics Artificial Intelligence
News headline image
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 of Wall Street’s Favorite Stock with Solid Fundamentals and 2 We Question
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
Topics Supply Chain
News headline image
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.